The US Food and Drug Administration (FDA) on November 9, 2026, announced new safety labelling requirements for popular diabetes and weight-loss medicines, including Ozempic, Wegovy, Mounjaro and Zepbound, citing a potential increased risk of a rare eye condition that can cause sudden and sometimes permanent vision loss. The condition, known as non-arteritic anterior ischaemic optic neuropathy (NAION), affects blood flow to the optic nerve. The warning applies to all medicines with glucagon-like peptide-1 receptor agonist (GLP-1 RA) activity.
Following its review of clinical trials, observational studies and adverse-event reports, the FDA has directed manufacturers to include the potential risk in the medicines’ ‘Warnings and Precautions’ section. However, the agency has not established a definitive causal relationship between the medicines and the condition. It has advised patients experiencing sudden vision changes to seek immediate medical attention rather than discontinue their medication without consulting a healthcare professional.
What Is NAION And Why Has The FDA Raised Concern?
NAION is a rare eye condition caused by reduced blood flow to the front portion of the optic nerve, which carries visual information from the eye to the brain. It can lead to sudden, painless vision loss, usually in one eye, and may cause permanent visual impairment. The condition is sometimes described as an ‘eye stroke’.
According to the FDA, symptoms may include sudden blurred vision, blind spots, missing portions of the visual field, distorted colours and reduced sharpness of central vision. Some patients may first notice these changes upon waking up. The agency has urged patients experiencing such symptoms to contact their healthcare professionals immediately and undergo an eye examination.
The FDA’s analysis of 126 randomised clinical trials involving 134,253 participants found 15 probable cases of NAION. Ten cases were reported among people receiving GLP-1 medicines, while five occurred among those receiving comparator treatments. The estimated incidence was 6.4 cases per 100,000 person-years among GLP-1 users, compared with 3.8 cases per 100,000 person-years in the comparison group.
These figures indicate that the condition remains uncommon. However, the difference in reported cases, alongside findings from observational studies, prompted the regulator to require additional safety information.
Earlier Studies Prompted A Wider Safety Review
The FDA’s investigation followed a July 2024 study published in JAMA Ophthalmology, which examined the possible association between semaglutide, the active ingredient in Ozempic and Wegovy, and NAION. Although the initial research had limitations, it prompted the regulator to investigate further. The agency subsequently examined clinical trial findings, animal research, reports of adverse reactions and observational studies involving patients using GLP-1 medicines.
Its review also found that the relationship is complex because several underlying health conditions associated with NAION, including diabetes, high blood pressure, smoking, sleep apnoea, anaemia and kidney disease, are also common among people prescribed these medicines. The FDA’s animal research did not identify a mechanism explaining how GLP-1 medicines could increase the risk. Meanwhile, the European Medicines Agency’s safety committee had previously identified NAION as a very rare side effect of semaglutide, estimating that it could affect up to one in 10,000 people taking the medicine for at least a year.
Pharmaceutical companies have also responded to the latest development. An Eli Lilly spokesperson told Reuters that the FDA communication applies to all medicines with GLP-1 activity and does not refer to findings specific to its products. The company said it was evaluating the update and would respond to the regulator. Novo Nordisk, which manufactures Ozempic and Wegovy, maintained that available data do not establish a cause-and-effect relationship and expressed confidence in the benefit-risk profile of its medicines. The companies’ responses highlight the continuing scientific debate surrounding the potential association.
The Logical Indian’s Perspective
Medicines that help people manage diabetes, obesity and other chronic health conditions can make a significant difference to their quality of life. However, their growing popularity must be accompanied by transparent communication about possible risks, responsible prescriptions and accessible medical guidance. The FDA’s decision is an important reminder that drug safety monitoring must continue even after medicines receive regulatory approval and become widely used. At the same time, a potential risk should not become a reason for unnecessary panic or self-medication decisions.
Patients should not abruptly stop prescribed GLP-1 medicines based on headlines or social media discussions. Instead, they should consult qualified healthcare professionals, understand their individual risk factors and seek immediate medical attention if they experience sudden changes in vision. Pharmaceutical companies, too, must prioritise patient safety and communicate emerging evidence transparently. How can healthcare regulators, pharmaceutical companies and doctors work together to ensure that patients receive both the benefits of new treatments and timely information about their potential risks?
Also Read: ‘This Is New Delhi’: Around 150 Chinese Vloggers Allegedly Pass Off Dhaka Slums As India’s Capital
